|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-6-11
|
|
pubmed:abstractText |
The aim of this study was to assess the feasibility of combining docetaxel, carboplatin, and gemcitabine (DoCaGem) as first-line treatment of ovarian and other müllerian origin tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
486-93
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12798716-Adult,
pubmed-meshheading:12798716-Aged,
pubmed-meshheading:12798716-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12798716-Carboplatin,
pubmed-meshheading:12798716-Deoxycytidine,
pubmed-meshheading:12798716-Dose-Response Relationship, Drug,
pubmed-meshheading:12798716-Epithelial Cells,
pubmed-meshheading:12798716-Female,
pubmed-meshheading:12798716-Humans,
pubmed-meshheading:12798716-Middle Aged,
pubmed-meshheading:12798716-Mullerian Ducts,
pubmed-meshheading:12798716-Ovarian Neoplasms,
pubmed-meshheading:12798716-Paclitaxel,
pubmed-meshheading:12798716-Taxoids
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
|
|
pubmed:affiliation |
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
